01/29/0

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Total Pages in this Submission

Docket No.

12273-3

(Only for new nonprovisional applications under 37 CFR 1.53(b))

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent app invention entitled:	lication for an					
Transgenic Plant-Based Vaccines	U.S. PTO					
and invented by:	09					
William H.R. LANGRIDGE; Jie YU and Takeshi ARAKAWA	109					
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:						
Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.:	60/178,403					
Continuation 🗆 Divisional 🗅 Continuation-in-part (CIP) of prior application No.:						
Which is a:						
Continuation Divisional Continuation-in-part (CIP) of prior application No.:						
Enclosed are:						
Application Elements						
1. 🗵 Filing fee as calculated and transmitted as described below						
<u> </u>						
2. Specification having 29 pages and including the following:						
a. 🗵 Descriptive Title of the Invention						
b. 🛛 Cross References to Related Applications (if applicable)						
c. 🛛 Statement Regarding Federally-sponsored Research/Development (if applicable)						
d. Reference to Microfiche Appendix (if applicable)	Reference to Microfiche Appendix (if applicable)					
e. 🗵 Background of the Invention						
f. 🗵 Brief Summary of the Invention						
g. 🛛 Brief Description of the Drawings (if drawings filed)						
h. 🗵 Detailed Description						
i. 🗵 Claim(s) as Classified Below						
j. 🛛 Abstract of the Disclosure						

# UTILITY PATENT AP ICATION TRANSMITTAL (Small Entity)

Docket No. 12273-3

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

	Application Elements (Continued)								
3.	B.   Drawing(s) (when necessary as prescribed by 35 USC 113)								
	a.	□ Formal							
· 4.		Oath or Declaration							
•	a.	☐ Newly executed (original or copy) ☐ Unexecuted							
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)							
•	C.	☐ With Power of Attorney ☐ Without Power of Attorney							
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).							
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.							
6.		Computer Program in Microfiche							
7.	X	Genetic Sequence Submission (if applicable, all must be included)							
	a.	☑ Paper Copy							
	b.	Computer Readable Copy							
	C.	Statement Verifying Identical Paper and Computer Readable Copy							
	Accompanying Application Parts								
8.		Assignment Papers (cover sheet & documents)							
9. ·		37 CFR 3.73(b) Statement (when there is an assignee)							
10 <sub>:</sub>		English Translation Document (if applicable)							
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations							
12.		Preliminary Amendment							
13.	X	Acknowledgment postcard							
14.	×	Certificate of Mailing    Specify Label No.): FL442633441US							

# UTILITY PATENT APTICATION TRANSMITTAL (Small Entity)

Docket No. 12273-3

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Accompanying Application Parts (Continued)								
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)						
16.		Small Entity Statement(s) - Specify Number of Statements Submitted:						
17.		Additional Enclosures (please identify below):						
		Decree A. The 4 Amelia etian Net De Dublished Duverget To 25 11 C.C. 422/b\/2\						
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)						
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.						
	Warning							
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.							

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. 12273-3

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

	$\sim 1$		4:		T	smittal
-00	Can	cilla	tian	ลทก	ıranı	emittai

#### **CLAIMS AS FILED** Fee For #Filed #Allowed #Extra Rate \$432.00 Total Claims 68 - 20 = 48 \$9.00 \$80.00 indep. Claims 5 - 3 <sup>-</sup>= 2 \$40.00 \$0.00 Multiple Dependent Claims (check if applicable) \$355.00 **BASIC FEE** \$0.00 OTHER FEE (specify purpose) **TOTAL FILING FEE** \$867.00

					<del></del>		
<b>X</b>	A che	ck in the amount of	\$867.00	to cover the f	iling fee is enclosed.		
×	The Commissioner is hereby authorized to charge and credit Deposit Account No.					19-2090	
	as described below. A duplicate copy of this sheet is enclosed.						
		Charge the amount	of	as filing fee	<b>e</b> .		
	X	Credit any overpaym	ent.				
` ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.							
☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,						wance,	
	•	pursuant to 37 C.F.F	R. 1.311(b).				
Date	ed: J:	anuary 29, 2001			Darl F	anh	
•		•			Siį	gnature	
					David A. Farah, M.D.		

CC: